Q3 2025 saw strong profit and margin growth, driven by operational improvements and a property sale, with MedTech, pharma, and defense offsetting weaker project volumes. The financial position is robust, supporting further investments and acquisitions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.